Clinical and pathological results of denosumab treatment for giant cell tumors of bone: Prospective study of 14 cases

Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery isthe commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclearfactor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL and itshuman monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of thisstudy was to evaluate clinical and pathological results of treatment of GCT with denosumab and to assessadverse effect proŞle and recurrence rate.Methods: Thirteen patients with 14 lesions were enrolled in the study. Mean age was 38.3 years. Patientswere given subcutaneous injections of denosumab (120 mg) every 4 weeks (with additional doses ondays 0, 8 and 15 in cycle 1 only) and were radiologically evaluated for tumor response. Pain and functional status were measured using Visual Analog Score (VAS) and Musculoskeletal Tumor Society Score(MSTS). Adverse effects were analyzed after each cycle.Results: Participants were 5 men and 8 women. Mean follow-up was 17 months. One lesion was Campanacci grade I, 8 were grade II, and 5 were grade III. Eight lesions were recurrent, and remaining wereprimary lesions. After average of 9 cycles (range: 4e17 cycles), all tumors underwent radiologicalregression. Ten lesions were removed surgically. More than 90% of giant cells were found to haveregressed in all pathological specimens. On last follow-up, average VAS was 1 and MSTS was 87%. Fatigueand joint and muscle pain after injections was reported by 46% of patients, and mild hypocalcaemia wasseen in 1 patient.Conclusion: Denosumab has been shown to be a successful drug in treatment of GCT. Denosumab can beused as neoadjuvant for all recurrent lesions, grade II lesions with high surgical risk, grade III lesions, andmetastatic cases of GCT.Level of evidence: Level IV, Therapeutic study© 2016 Turkish Association of Orthopaedics and Traumatology. Publishing services by Elsevier B.V. This isan open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

___

Balke M, Schemper L, Gebert C, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):949e978.

Dominkus M, Ruggieri P, Bertoni F, et al. Histologicallay veriŞed lung metas- tases in benign giant cell tumors-14 cases from a single institution. Int Orthop. ;30:499e504. Turcotte RE. Giant cell tumor of bone. Orthop Clin North Am. 2006;37:35e51.

Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Gi- ant cell tumor of bone. Am J Clin Oncol. 2006;29(1):96e99.

Cowan RW, Singh G. Giant cell tumor of bone: a basic science perpective. Bone. ;52(1):238e246.

Skubitz KM. Giant cell tumor of bone: current treatment options. Curr Treat Options Oncol. 2014;15(3):507e518.

Prosser GH, Baloch KG, Tillman RM, Carter SR, Grimer RJ. Does curettage without adjuvan therapy provide low recurrence rates in giant cell tumors of bone? Clin Orthop. 2005;435:211e218.

Micke O, Bruns F, Eich HT, et al. Radiation therapy for giant cell tumor of bone: Long-term results of a multicenter study in Germany. Int J Radiat Oncol Biol Phys. 2005;63:108.

Hosalkar HS, Jones KJ, King JJ, Lackman RD. Serial arterial embolization for large sacral giant-cell tumors: mid- to long-term results. Spine. 2007;32:1107e1115.

Daugall WC, Glaccum M, Charrrier K, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412e2424.

Atkins GJ, Kostakis P, Vincent C, et al. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow and giant cell tumor of bone. J Bone Min Res Off J Am Soc Bone Min Res. 2006;21: e1349.

Morgan T, Atkins GJ, Trivett MK, et al. Molecular proŞling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappaB. Am J Pathol. 2005;167:117e128.

Skubitz KM, Cheng EY, Clohisy Dr, Thompson RC, Skubitz AP. Gene expression in giant -cell tumors. J Lab Clin Med. 2004;144:193e200.

McClung MR, Lewiecki EM, Cohen SB, et al. AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821e831.

Cummings SR, San MArtin J, McClung MR, et al. FREEDOM Trial. Denasumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756e765.

Stopeck AT, Lipton A, Body JJ, et al. Denosumab compared with zolendronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double blind study. J Clin Oncol. 2010;28:5132e5139.

Thomas D, Henshaw R, Skubitz KM, et al. Denosumab in patients with giant cell tumor of bone: an open label, phase 2 study. Lancet Oncol. 2010;11:275e280.

Lopez-Pousa A, Broto JM, Garrido T, Vazguez J. Giant cell tumor of bone: new treatments in development. Clin Transl Oncol. 2015;17:419e430.

Campanacci M, Giunti A, Olmi R. Metaphyseal and diaphyseal localization of giant cell tumors. Chir Organi Mov. 1975;62(1):29e34.

Chawla S, Henshaw R, Seeger L, et al. Safety and efŞcacy of denosumab for adults and sklettaly mature adolescents with giant cell tumor of bone: interim analysis of an open-label, paralel-group, phase 2 study. Lancet Oncol. 2013;14: e908.

Enneking WF1, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin Orthop Relat Res. 1993 Jan;286:241e246.

Gao ZH, Yin JQ, Xie XB, et al. Local control of giant cell tumors of the long bone after agressive curettage with and without bone cement. BMC Musculoskelet Disord. 2014;15(2):330. van der Heijden L, Dijkstra PD, van de Sante MA, et al. The clinical approach toward giant cell tumor of bone. Oncologist. 2014;19(5):550e561.

Emori M, Kaya M, Sasaki M, Wada T, Yamaguchi T. YamashitaT. Preoperative selective arterial embolization as a neoadjuvant therapy for proximal humerus giant cell tumor of bone: radiological and histological evaluation. Jpn J Clin Oncol. 2012;42:851e855.

Yasko AW. Interferon therapy for giant cell tumor of bone. Curr Opin Orthop. ;17:568e572.

Balke M, Campanacci L, Gebert C, et al. Biphosphonate treatment of aggressive primary, recurrent and metastatic giant cell tumor of bone. BMC Cancer. ;10:462. Thomas DM. RANKL, denosumab and giant cell tumor of bone. Curr Opin Oncol. ;24:397e403.

Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer. ;97:2520e2529.

Wojcik J, Rosenberg AE, Bredella MA, Choy E, Nielsen GP, Deshpande V. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol. 2016;40(1):72e80.

Aponte-Tinao L, Piuzzi NS, Roitman P, Farfalli GL. A high grade sarcoma arising in a patient with recurrent benign giant cel tumor of the proximal tibia while recieving treatment with denosumab. Clin Orthop Relat Res. 2015;473: e3055.

Lau CPY, Huang L, Wong KC, Kumta SM. Comparison of the anti-tumor effects of denosumab and zolendronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connect Tissue Res. 2013;54(6):439e449.

Rutkowski P, Ferrari S, Grimer R, et al. Surgical downstaging in an open-label plase II trial of denosumab in patients with giant cell tumor of bone. Ann Surg Oncol. 2015;22:2860e2868.